Tesofensine
Metabolic Health · Triple monoamine reuptake inhibitor
Tier D+
What this is
Saniona now developing for hypothalamic obesity (rare disease orphan indication). Substantial weight loss in obesity trials. Cognitive trials disappointed. Research chem availability exists; caution with CV effects.
Mechanism
Inhibits DAT, NET, SERT; originally developed by NeuroSearch for Alzheimer's/Parkinson's (failed primary endpoints); repurposed for obesity with striking weight loss effects
Dose & route
0.25-1 mg/day PO in obesity trials
Citations
- https://pubmed.ncbi.nlm.nih.gov/18206399/
- https://pubmed.ncbi.nlm.nih.gov/18842805/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC9269579/
- https://pubmed.ncbi.nlm.nih.gov/40843857/
- https://doi.org/10.4274/jcrpe.galenos.2025.2025-12-12
- https://pubmed.ncbi.nlm.nih.gov/18950853/
- https://www.sciencedirect.com/science/article/abs/pii/S0140673608615251
- https://en.wikipedia.org/wiki/Tesofensine
Links go to the source. If a link is dead or you want something re-checked, let me know.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.